BNET Industries

Market Cap:$147.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Can Roche Leave Genentech Alone?
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
jim edwards and pfizer inc. and pharmaceutical company - All News and Analysis
The 10 Weirdest Drug Stories of the Month
April 2009 has come and gone, and once again it is time for BNET's roundup of the top 10 weirdest drug stories of the month. Enjoy! Bayer has a flock of sheep mow its lawn About 1450 sheep grazed Bayer's Richmond, Calif., campus last nonth, eating...
Pfizer, Vertex Execs Are Victims of Facebook Faker; Forbes, WSJ Also Targeted
Someone is impersonating prominent members of the pharma and biotech world on Facebook, including Vertex Pharmaceuticals chief executive Joshua Boger, a chief science officer at Pfizer and Forbes drug writer Matt Herper. by Jim Edwards
Claim: LeCarre's "The Constant Gardener" Was Based on Pfizer Trovan Case
The Connecticut Law Tribune claims that The Constant Gardener, a John Le Carré book and later a movie with the same name, is in fact based on the Pfizer Trovan case. But is the claim true? A look at the timeline of both the case and the book suggest it...
Starved of News, Press Speculates on Deals for Abbott, Pfizer and Wyeth
New Year is a slow news period, which is why the business press filled up with next-to-useless corporate strategy stories about Abbott Labs, Wyeth and Pfizer. The one thing these stories all have in common? They're long on speculation and short on substance. Let's take them one at a time....
Obama Already Turning Into a Nightmare for Big Pharma
President Barack Obama's new chief of staff, Rahm Emanuel, is turning out to be Big Pharma's worse nightmare. He twice put out press releases backing the crusade of Peter Rost, the former Pfizer vp turned whistleblower, in favor of allowing drug reimportation from foreign countries to encourage price competition. (See...
The 10 Weirdest Drug Stories of the Month
Another page has been torn off the calendar, and that means it's time to open up Big Pharma's vault of peculiarities and do a roundup of strange-but-true tales from the world of drugs that surfaced on my radar last month. I give you the 10 weirdest drug...
Pharma's Deal-Making Frenzy: Lots of Noise, Less Substance
Reading the mainstream press over the last few weeks could give you the strong impression that pharma has entered a phase of deal-making frenzy. Here's how Reuters describes it today: Big pharmaceutical companies are set to step up the hunt for assets to buy in promising fields like biotechnology,...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
